Evaluation of the antianginal effect of isosorbide-5-mononitrate in patients with chronic stable angina pectoris.
The antianginal and anti-ischemic properties of isosorbide-5-mononitrate (ISMN) were evaluated in 40 patients with chronic stable angina pectoris in a randomized double-blind parallel-group placebo-controlled study. After 2 weeks' placebo run-in period the patients were randomized to either ISMN, orally 20 mg 2-3 times daily (titrated) or placebo. They underwent bicycle exercise stress test at the end of the placebo period and after 4 weeks of treatment. Compared with placebo ISMN increased the exercise performance, reduced ST-segment depression, anginal frequency and sublingual nitroglycerin consumption. All these changes were statistically significant. It may be concluded that ISMN is an effective antianginal and anti-ischemic agent in patients with chronic stable angina pectoris.
Yasky
J
J
Facultad de Farmacia y Bioquímica, Universidad Juan Agustín Maza, Mendoza, Argentina.
Ontanilla
E
E
Koch
J E
JE
D000328:Adult; D000787:Angina Pectoris / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control*; D001794:Blood Pressure; D002908:Chronic Disease; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D006339:Heart Rate; D006801:Humans; D007548:Isosorbide Dinitrate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate